CSPC PHARMA's innovative drug SYH2085 has been approved to conduct clinical trials
CSPC PHARMA (01093.HK) announced that the Group's developed chemical Class 1 innovative drug SYH2085 tablets have been approved by the National Medical Products Administration of China to conduct clinical trials in China. The approved clinical indication is for the treatment of uncomplicated influenza A and B in adults and adolescents aged 12 and above
Source: AASTOCKS The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments